



Ads by Google

Stop seeing this ad

Why this ad?

The NEW ENGLAND
JOURNAL of MEDICINE

CORRESPONDENCE

Hydroxychloroquine in Hospitalized Patients with Covid-19

February 10, 2021

DOI: 10.1056/NEJMc2035374

[Metrics](#)[Related Articles](#)

TO THE EDITOR

We were surprised by the hydroxychloroquine dose chosen in the Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial conducted by Horby et al. (Nov. 19 issue).¹ In this trial, patients received a higher dose of hydroxychloroquine (4 g cumulated over the first 3 days) than that administered in the trial conducted by Lagier et al.² (600 mg per day), and it was similar to that in the trial conducted by Borba et al.³

In vitro studies show that the effect of hydroxychloroquine is mainly mediated by alkalization of the phagolysosomes,⁴ where it can concentrate about 1500 times more than in plasma. This effect can be obtained with low doses of hydroxychloroquine because of its long elimination half-life. High doses may therefore be useless or even deleterious because of the anti-interferon action of hydroxychloroquine,⁵ which may result in a more severe form of Covid-19.⁶ The dose used in the RECOVERY trial, the second highest after that in the trial conducted by Borba et al., arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.

Alexis Lacout, M.D.

Surgical Medical Center of Tronquieres–Elsan, Aurillac, France

Christian Perronne, M.D., Ph.D.

Versailles Saint-Quentin-en-Yvelines University, Garches, France

Valere Lounnas, Ph.D.

European Molecular Biology Laboratory, Heidelberg, Germany

No potential conflict of interest relevant to this letter was reported.

This letter was published on February 10, 2021, at NEJM.org.

[6 References](#) ▼

RESPONSE

The authors reply: Hydroxychloroquine was evaluated in the RECOVERY trial primarily as an antiviral drug. Hydroxychloroquine and chloroquine show only modest antiviral activity in cell-culture systems. The dosing schedule of hydroxychloroquine in the

RECOVERY trial was therefore designed to provide the highest tissue concentrations that were safe in order to provide the maximum antiviral activity and thus the best chance of therapeutic benefit.¹ These doses were based on pharmacokinetic modeling in malaria and rheumatologic conditions and were informed by safety thresholds determined from toxicokinetic data on intentional overdoses with the closely related chloroquine.²

The base equivalent maintenance doses studied in the RECOVERY and World Health Organization (WHO) Solidarity trials³ are approximately half those evaluated in the study of chloroquine by Borba et al.⁴ Whereas the dosing schedule in the trial conducted by Borba et al. was predicted to confer an increased risk of toxicity,² the dosing schedule in the RECOVERY and WHO Solidarity trials was not. There was no evidence of cardiovascular toxicity in either trial. We know of no evidence that the anti-interferon activity of hydroxychloroquine would affect disease progression in hospitalized patients.

Peter Horby, F.R.C.P.

Nicholas J. White, F.R.S.

Martin J. Landray, F.R.C.P.

University of Oxford, Oxford, United Kingdom

recoverytrial@ndph.ox.ac.uk

Since publication of their article, Drs. Horby and Landray report receiving donated supplies of the REGN-COV2 monoclonal antibody cocktail for use in the RECOVERY trial from Regeneron Pharmaceuticals. No further potential conflict of interest relevant to this letter was reported.

This letter was published on February 10, 2021, at NEJM.org.

4 References ▾

More from the week of February 11, 2021

← →

CLE

Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

· Trial Consortium

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL

Case 4-2021: A 70-Year-Old Woman with Dyspnea on Exe

R.M. Schwartzstein and Others



The image shows two overlapping digital screens displaying the NEJM website. The top screen shows the NEJM Group header with 'Follow Us', 'Sign In', 'Create Account', and 'SUBSCRIBE' buttons. Below the header, the 'COVID-19' section is highlighted. The main content area features a graph titled 'mRNA-Based Covid-19 Vaccine in Nonhuman Primates' showing AUC (log₁₀) on the y-axis (0 to 6) and time points on the x-axis (Before Vaccination, 2 Wk after First Vaccination, 4 Wk after Second Vaccination). The graph compares two groups: 10 µg mRNA-1273 (blue line) and 100 µg mRNA-1273 (red line). The 100 µg group shows higher AUC values across all time points. Below the graph, the article title 'mRNA-Based Covid-19 Vaccine in Nonhuman Primates' is displayed, followed by the authors 'K.S. Corbett and Others' and a brief summary of the study. To the right of the graph, there is an 'EDITORIAL' section titled 'Dexamethasone and Covid-19' and an 'ORIGINAL ARTICLE' section titled 'Hydroxychloroquine with or without Azithromycin in Covid-19'. The bottom screen shows the 'Multimedia' section with a featured article 'The Game Is Afoot' by N. Yazdani and Others, which includes an interactive medical case. A large, semi-transparent text overlay reads 'Fast. Essential. Inspiring. Subscriber Access.' with a 'SUBSCRIBE TODAY →' button. Below the button, the text 'or Renew' is visible.